Synlogic, Inc. (SYBX): Free Cash Flow
-$4.36M
Year ended 2025-12-31
| Period ended | Free Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$4.36M | n/m | 2026-03-12, From 2025-01-01 |
| 2024-12-31 | -$31.67M | n/m | 2026-03-12, From 2024-01-01 |
| 2023-12-31 | -$51.83M | n/m | 2025-03-06, From 2023-01-01 |
| 2022-12-31 | -$57.62M | n/m | 2024-03-19, From 2022-01-01 |
| 2021-12-31 | -$52.88M | n/m | 2023-03-29, From 2021-01-01 |
| 2020-12-31 | -$39.95M | n/m | 2022-03-17, From 2020-01-01 |
| 2019-12-31 | -$76.72M | n/m | 2021-03-25, From 2019-01-01 |
| 2018-12-31 | -$48.12M | n/m | 2020-03-12, From 2018-01-01 |
| 2017-12-31 | -$33.63M | n/m | 2019-03-12, From 2017-01-01 |
| 2016-12-31 | -$22.25M | n/c | 2018-03-20, From 2016-01-01 |
| 2015-12-31 | -$21.39M | n/m | 2017-03-15, From 2015-01-01 |
| 2014-12-31 | -$14.07M | n/m | 2017-03-15, From 2014-01-01 |
| 2013-12-31 | -$6.50M | n/a | 2016-03-30, From 2013-01-01 |
Free Cash Flow at similar companies
| Company | Year ended | Free Cash Flow | Change YoY |
|---|---|---|---|
| Synlogic, Inc. (SYBX) | 2025-12-31 | -$4.36M | n/m |
| Abbott Laboratories (ABT) | 2025-12-31 | $7.39B | +16.4% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $12.85B | -7.9% |
| Pfizer Inc (PFE) | 2025-12-31 | $9.07B | -7.7% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $19.70B | -0.7% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $28.84M | +101.3% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $12.36B | -31.7% |
| Lisata Therapeutics, Inc. (LSTA) | 2025-12-31 | -$15.98M | n/m |
| Heron Therapeutics, Inc. (HRTX) | 2025-12-31 | -$27.91M | n/m |
Compare SYBX, ABT, BMY, PFE side by side · Screen every company in Pharmaceutical Preparations ↗